Related by context. All words. (Click for frequent words.) 67 cEVR 66 complete Early Virological 65 rapid virologic response 65 rapid virological response 62 undetectable HCV RNA 62 chronic HCV genotype 62 undetectable virus HCV 62 8mg/kg 61 treatment naïve genotype 60 log# reduction 60 genotype 1b 60 Sustained virologic response 59 treatment naive genotype 59 RNA copies mL 58 ug dose 58 IU mL 58 IU ml 58 mcg BID 58 mg TID 58 achieved ACR# 58 HIV coinfected 58 patients coinfected 57 #mg BID [002] 57 stage IIIb IV 57 ACTEMRA TM 57 3mg/kg 57 biochemical relapse 57 serum aminotransferase levels 57 reduce serum phosphate 57 HBeAg negative 57 recurrent genital herpes 57 log# copies mL 57 mL/min/#.# m2 57 DAS# CRP 56 creatinine ratio 56 x ULN 56 mg QD 56 ug kg 56 μg dose 56 antiretroviral naïve 56 virologic response EVR 56 humanized interleukin 6 56 prednisone prednisolone plus 56 Index CDAI 56 Pneumocystis pneumonia PCP 56 #mg BID [001] 56 HBeAg seroconversion 56 plasma HCV RNA 56 hypophosphatemia 56 virologically suppressed 56 HCV genotype 56 mg/m2 dose 56 plus prednisone prednisolone 55 detectable HCV RNA 55 hepatitis C genotype 55 CCyR 55 ® emtricitabine 55 relapsed MM 55 Ishak fibrosis score 55 naïve HCV 55 antibody titer 55 CIMZIA TM 55 Stage IIB 55 q#h 55 HBeAg + 55 4mg/kg 55 Pegasys plus Copegus 55 progression TTP 54 QTcF 54 e antigen HBeAg 54 ug ml 54 REMICADE monotherapy 54 mg q#h 54 RELEASE ACCORDING TO 54 mitoxantrone plus 54 achieved sustained virologic 54 elevated transaminases 54 mg eq 54 #mg dose [002] 54 achieved undetectable HCV 54 plus methotrexate 54 dizziness nausea diarrhea 54 sustained virologic response 54 sUA 54 log# IU mL 54 FOLFOX6 54 pmol L 54 lymphocytosis 54 infliximab monotherapy 54 mU liter 54 morphometric vertebral fractures 54 achieved CCyR 54 ribavirin therapy 54 alanine aminotransferase 54 genotypic resistance 54 Virologic failure 54 #mg QD [002] 54 highly emetogenic 54 COMBIVIR 54 plus dexamethasone 54 log# 54 lactate dehydrogenase LDH 54 underwent surgical resection 54 PEGylated Fab fragment 54 achieved mucosal healing 54 urine albumin 54 aspartate aminotransferase 54 Hb A1C 53 minimally symptomatic 53 Engerix B 53 resistant hormone refractory 53 seroprotection 53 MIC# [001] 53 alfa 2a 53 ALT elevation 53 LEXIVA r 53 -#.# log# 53 telaprevir dosed 53 fatigue asthenia 53 HBeAg positive 53 mg BID 53 q8h 53 mL sec 53 #mg BID [003] 53 undetectable viral load 53 recurrent glioblastoma multiforme 53 serum phosphorous 53 piperacillin tazobactam 53 stage IIIB 53 lopinavir r arm 53 #.#-#.# [011] 53 #mg q8h 53 MCyR 53 mg/# h 53 VELCADE melphalan 53 moderately emetogenic 53 baminercept 53 mL/min/#.# m 2 53 plus aztreonam 53 generalized edema 53 unresectable HCC 53 nevirapine regimen 53 Peginterferon alfa 2b 53 corticosteroid dose 53 g trans fats 53 Pharmacokinetic parameters 53 #mg/m# [001] 53 serum urate 53 sustained virological response 53 receiving INTRON 53 mg/m2/day 53 SVR# 52 MAGE A3 ASCI 52 pegIFN 52 MLP Affiliate 52 mcg albinterferon alfa 2b 52 % AST SGOT 52 Viral load 52 low dose cytarabine 52 pegylated interferon alfa 2a 52 neutropenia dehydration dyspnea 52 Nephrol Dial Transplant 52 RECIST criteria 52 intravenous bolus 52 #.#ng/ml 52 mcg mL 52 dosing cohorts 52 BARACLUDE ® 52 -#.# mg dL [002] 52 linaclotide treated 52 R# #mg BID 52 lopinavir r 52 blastic phase 52 aspartate aminotransferase AST 52 gemcitabine carboplatin 52 mg kg dose 52 ACR# response 52 severe neutropenia 52 Peginterferon Alfa 2a 52 acute febrile 52 PROCTOCORT ® Suppository Hydrocortisone 52 PEG IFN 52 ACR# [002] 52 undetectable viral 52 coinfected 52 CR nPR 52 Virologic 52 Lupuzor ™ 52 μmol L 52 seropositivity 52 microbiological eradication 52 mIU ml 52 Operative mortality 52 plus OBT 52 nucleoside naive 52 bortezomib refractory 52 μg kg 52 autoantibody positive 52 abnormal cytology 52 achieve sustained virological 52 #.#g/day 52 microgram kg 52 octreotide LAR 52 aplastic anemia AA 52 #mg/kg [002] 52 weekly CSBMs 52 Severity Index PASI 52 glycated hemoglobin levels 52 virologic response 52 & s2 = 52 adefovir treated 52 mcg QD 52 oral FTY# 52 TMC# r 52 http:/events.fai.org 52 SCr 52 Crohn Disease Activity 52 Circumcised men 52 copies mL 52 PLX STROKE targeting 52 mg kg hr 52 subcutaneous PRO 52 hemagglutination inhibition 52 % CI #.#-#.# [003] 52 alanine aminotransferase ALT 52 HAM D# scores 52 cGy 52 mg m² 52 isoniazid preventive therapy 52 baseline HbA1c 52 NNT = 52 HIV RNA 52 mso footer margin 52 receiving VICTRELIS 52 aged ≥ 52 virologic failure 51 Acetate Rectal Suppositories 51 oxycodone CR 51 placebo PBO 51 DLTs 51 Mg Uk 51 K ras mutations 51 somatostatin analog 51 EDSS score 51 elevated ALT 51 baseline serum creatinine 51 mg/# hours 51 Peg IFN 51 pegylated interferon alpha 51 NR CC 51 HCV genotype 1 51 serum ALT 51 chronic HCV infection 51 adjunctive placebo 51 placebo dexamethasone 51 decompensated liver disease 51 Myelosuppression 51 Forodesine HCl 51 atazanavir ritonavir 51 Response Evaluation Criteria 51 telaprevir pegylated interferon 51 refractory NSCLC 51 Zidovudine Tablets 51 oral ridaforolimus 51 achieved PASI 51 ps :# 51 carboplatin AUC 51 μg doses 51 golimumab CNTO 51 cisplatin vinorelbine 51 CHANGE WEEKLY CHANGE 51 iniparib BSI 51 CDAI score 51 μg L 51 Median PFS 51 tumor progression TTP 51 non splenectomized 51 undetectable HBV DNA 51 ACR# ACR# 51 Oral Fingolimod 51 respirable droplets delivered 51 Non inferiority 51 serum HCV RNA 51 weekly subcutaneous injections 51 DAS# [002] 51 oral prednisone 51 cells mcL 51 aminotransferase elevations greater 51 mg dosed twice 51 Mg Usa 51 Suppository Hydrocortisone Acetate Rectal 51 -#.# log# copies mL 51 CRp 51 combination antiretroviral therapy 51 REYATAZ r 51 mg Pycnogenol 51 jana.mlcochova @ thomson.com 51 timepoint 51 5-FU/LV 51 μg d 51 hour bronchodilation 51 mmol l 51 budesonide pMDI 51 CLL SLL 51 ertapenem 51 forodesine 51 PEG Interferon alfa 51 RGT arm 51 seronegative 51 liver histology 51 FOLFIRI alone 51 prior chemotherapy regimens 51 dosing cohort 51 MADRS score 51 reactogenicity 51 IRLS score 51 bone marrow reticulin deposition 51 PegIFN 51 macroalbuminuria 51 metformin monotherapy 51 Available Seat Kilometres ASKs 51 tolterodine ER 51 spontaneous bowel movements 51 Free Survival PFS 51 TAXUS p value 51 mIU mL 51 Repliform R revenues 51 confirmed CCyR 51 aminotransferase levels 50 serum HBV DNA 50 mcg dose 50 Fasting blood glucose 50 X ULN 50 PAOD 50 Cmax 50 certolizumab 50 Ceplene/IL-2 50 pT3 50 protease inhibitor PI 50 Tasigna prolongs 50 J Am Podiatr 50 hyperphenylalaninemia HPA due 50 #mg/day [002] 50 peginterferon alfa 2a 50 Solid Tumors criteria 50 randomized #:#:# 50 concentration Cmax 50 lymphoid blast 50 % 3C/script 50 Cream USP 1 50 Severe acneform rash 50 ALT flares 50 HCV Genotype 50 ug mL 50 IFN alfa 50 plus prednisone 50 MLN EUROS 50 HPV-#/# 50 CrCl 50 g dl 50 PASI scores 50 HCV RESPOND 2 50 induction regimen 50 lopinavir ritonavir plus 50 q#d 50 #ng/ml 50 REYATAZ r arm 50 cyclophosphamide methotrexate 50 mg ustekinumab 50 pegylated IFN 50 apolipoprotein B 50 achieve sustained virologic 50 CTAP# Capsules 50 #.#mg/kg [002] 50 nadroparin 50 CR CRu 50 rFSH 50 PREZISTA r 50 R LAV 50 PREZISTA r arm 50 Pharmacokinetics PK 50 human Chorionic Gonadotropin 50 histologically confirmed 50 plus gemcitabine 50 perinatal transmission 50 evaluable subjects 50 EGYPTIAN POUND 50 mcg kg 50 Soriatane R acitretin capsules 50 mg subcutaneously 50 coinfection 50 doxorubicin cyclophosphamide 50 remission CR 50 serum sodium concentration 50 pulmonary exacerbations 50 ACR# responses 50 tipranavir r 50 dose cohort 50 mg orally 50 CIMZIA TM certolizumab pegol 50 aminotransferases 50 % mlink 50 advanced hepatocellular carcinoma 50 rimonabant #mg/day 50 mg qd 50 piotr.skolimowski @ thomson.com 50 SGPT 50 baseline LDH 50 hepatorenal syndrome 50 PSADT 50 % Confidence Interval 50 continuous intravenous infusion 50 baseline neutrophil counts 50 mcg kg REBETOL 50 hemoglobin A1c HbA1c 50 Soyabean Ext Bulk 50 gemcitabine cisplatin 50 virologically 50 CIMZIA ™ 50 urinary albumin excretion 50 hours postdose 50 pegylated alpha interferon 50 ISLAND Yawgoo Valley 50 tumors GIST 50 biologic DMARD 50 moderate renal impairment 50 pyrazinamide 50 ritonavir boosted 50 HUMIRA achieved PASI 50 MBq 50 Folfox 50 lipoprotein Lp 50 hypokalemia 50 complete cytogenetic response 50 seroconverted 50 null responders 50 Timed Walk 50 â ‰ ¥ 50 RECIST Response Evaluation Criteria 50 NMIBC 50 virological response 50 Islands Sportfishing 50 #mg/day [001] 49 Febrile neutropenia 49 mU L 49 baseline A1C 49 peginterferon 49 fasting plasma glucose FPG 49 invasive aspergillosis 49 mcg Albuferon 49 mRCC 49 seroconversion 49 HT 1A 49 mcg linaclotide 49 mg/m2 49 PEGylated anti 49 EGFR TKI 49 Median progression 49 cells/mm3 49 ABILIFY Injection 49 viral titers 49 % MID-EAST/AFRICA 49 lumbar spine BMD 49 timepoints 49 Hazard Ratio HR 49 rectal tenesmus 49 microliter 49 telaprevir dosing 49 brand ciclesonide HFA 49 mg p = 49 Acute myeloid leukemia 49 #mg/dl 49 TNF alpha IL 49 #mg QD [001] 49 chronic HBV 49 symptomatic intracranial hemorrhage 49 abdominal distention 49 COPEGUS 49 DAS# remission 49 free survival PFS 49 Payout ratio 49 Active Ulcerative Colitis 49 clinically meaningful improvement 49 ribavirin RBV 49 serum IGF 49 calculated creatinine clearance 49 achieved statistical significance 49 pCR 49 serologically active patients 49 Annualized ROE 49 Adjuvant chemotherapy 49 dapagliflozin plus 49 mcg doses 49 mmHg diastolic 49 #mg #mg #mg [003] 49 intramuscularly 49 copies ml 49 intramuscular dose 49 Bezielle 49 ALT normalization 49 statistical significance p 49 Castration Resistant Prostate Cancer 49 abacavir lamivudine 49 Zevalin R Ibritumomab 49 mg XP# 49 myelodysplastic myeloproliferative diseases 49 Gary Densham Monte Carlo 49 R entecavir 49 mucosal healing 49 mg/m2 IV 49 ritonavir boosted atazanavir 49 comparator arm 49 Miwah Gold Prospect 49 neutrophil counts 49 INCOME TAX EFFECTS 49 INVEGA ® 49 partial remissions 49 anthracycline taxane 49 Nonperforming loans totaled 49 Multikine patented 49 mEq L 49 TOTAL OFFENSIVE PLAYS . 49 undergone splenectomy 49 Index CDAI score 49 dasatinib Sprycel ® 49 ARCALYST ® 49 mg calcium 49 mg subcutaneous 49 oral allopurinol 49 Postoperatively 49 QRS duration 49 #mV V 49 R LANV CC 49 GOUT 49 Habitual snoring 49 CDAI 49 urinary N telopeptide 49 FluCAM 49 receiving highly emetogenic 49 Sustained virological response 49 Aptivus ® 49 #mg/m# [002] 49 mg simvastatin 49 EGFR mutation positive 49 salmeterol fluticasone propionate 49 FTE staffing 49 transaminases 49 cytidine nucleoside analog 49 nodular partial response 49 Besivance TM 49 squamous histology 49 antiviral efficacy 49 posaconazole 49 mIU L 49 HER2 positivity 49 Chronic pancreatitis 49 glomerular filtration 49 CTEPH 49 unresectable Stage III 49 Persistent Sleep 49 mm ³ 49 saline placebo 49 mg Androxal 49 Amgen Neulasta ® 49 Adjusted EBITDAR margin 49 transaminase 49 mmHg systolic 49 HbA 1c 49 CIN3 49 Solid Tumors RECIST 49 TMC# [002] 49 genital lesions 49 KRAS mutant tumors 49 HAQ DI 49 Decitabine 49 mg RDEA# 49 adjunctive ABILIFY 49 STRIDE PD 49 HBsAg 49 Virulizin ® 49 abnormal p# biomarker 49 mg BID dose 49 oral diclofenac 49 HBV DNA levels 48 HER2 expression 48 CD4 lymphocyte count 48 Systemic Sclerosis 48 normal ULN 48 BCG vaccinated 48 concomitant antibiotics 48 #mg ATC 48 opioid induced constipation OIC 48 mCi 48 nevirapine NVP 48 -#.# mg dL [001] 48 Primary endpoints 48 Zometa hazard 48 response CCyR 48 PegIFN RBV 48 echocardiographic parameters 48 lamivudine refractory patients 48 evaluable patients 48 pg ml 48 peg IFN 48 seropositive patients 48 antiretroviral naive 48 colorectal carcinoma 48 refractory AML 48 zidovudine lamivudine 48 Expanded Disability Status 48 XL# administered orally 48 oral methylnaltrexone 48 WEEK ENDING INDEX 48 mso header 48 -pass code SHOPNBC 48 metastatic renal cell 48 Platelet counts 48 PSA nadir 48 Eur J Endocrinol 48 CK # plasma concentrations 48 mCRPC 48 Kidney Int 48 scores TNSS 48 anthracycline containing 48 Apidra ® 48 estimated glomerular filtration 48 mg tid 48 experienced virologic failure 48 KRAS mutations occur 48 hematologic toxicity 48 cells uL 48 NNRTI resistance 48 BBB Baa BB 48 #μg [001] 48 NovoLog ® Mix 48 oral vancomycin 48 6MWD 48 ml min 48 XIENCE V vs. 48 mcg kg min 48 phase IIb study 48 oral antidiabetic medication 48 valacyclovir 48 TLUS 48 del 5q MDS 48 albumin excretion 48 Arch Intern Med 48 Ann Oncol 48 TEAEs 48 HGPIN 48 Gov't imposes 48 - -winger Colby Armstrong 48 anagrelide 48 CIN3 + 48 Proc Am 48 interquartile range 48 nonmetastatic 48 minimally symptomatic metastatic castrate 48 adrian.krajewski @ thomson.com 48 + - Vulnerable 48 Viread Emtriva Sustiva 48 SELENA SLEDAI score 48 aminotransferase ALT 48 subcutaneously administered 48 NRTI backbone 48 underwent resection 48 PRADAXA #mg 48 virological failure 48 elevated serum creatinine 48 specific alkaline phosphatase 48 neuropathy sensory 48 fraction LVEF 48 CSBM 48 umol L 48 mg niacin 48 See CONTRAINDICATIONS 48 pericardial effusion 48 ng dL 48 BMS p = 48 TNF Tumor Necrosis Factor 48 azilsartan medoxomil 48 Hycamtin ® 48 median PFS 48 sUA levels 48 CIMZIA R 48 lopinavir ritonavir Kaletra 48 interleukin IL -6 48 serum potassium 48 abdominal pain flatulence 48 visilizumab 48 bronchial hyperresponsiveness 48 FEET FLOODING 48 mCi kg 48 HbA1C levels 48 Hamilton Anxiety Scale 48 postdose 48 secondary efficacy endpoint 48 J Am Coll 48 pmol liter 48 clinically evaluable patients 48 Aflibercept 48 creatinine clearance 48 pT2 48 locoregional recurrence 48 AZT 3TC 48 -#.# USD JPY [002] 48 daunorubicin 48 APNB 48 administered subcutaneously 48 Emtriva Viread 48 suppl #S #S 48 dexamethasone Decadron 48 μg dl 48 evaluating tivozanib 48 ancrod 48 μg mL 48 liver enzymes ALT 48 Secondary endpoints included 48 Duration Gap 48 pegylated interferon alfa 48 inhibitory concentration 48 viral kinetics 48 emtricitabine tenofovir 48 HCV RNA 48 nonnucleoside reverse transcriptase inhibitors 48 Solid Tumors 48 leucopenia 48 HBsAg positive 48 mm Hg systolic 48 castrate resistant 48 lymphocyte count 48 administering XIFAXAN 48 Thal Dex 48 colorectal adenoma 48 APTIVUS r 47 progesterone receptor negative 47 FOLFOX4 alone 47 advanced adenoma 47 GSK# [001] 47 endoscopic remission 47 HIV uninfected 47 #.#/#.# mmHg [001] 47 castrate resistant prostate cancer 47 rizatriptan 47 F FLT 47 + Pd g t 47 RESIST studies 47 Psoriasis Area 47 ARB telmisartan 47 mild renal impairment 47 virologic 47 LANTUS R 47 mutated KRAS 47 ABRAXANE therapy 47 peginterferon alfa 2b 47 Viread Emtriva 47 metastatic hormone refractory 47 mg d 47 glycosylated hemoglobin HbA1c 47 Pegasys ® 47 HER2 negative 47 Secondary endpoints include 47 cytogenetic response 47 brivaracetam 47 thrombin inhibiting aptamer 47 endometrial ovarian 47 FUSILEV enhances 47 interferon alfa 2a 47 Capitalised terms used 47 riociguat 47 dose escalation phase 47 intradermal injections 47 mm Hg diastolic 47 statin monotherapy 47 antibody titers 47 lactate dehydrogenase 47 argc 47 leukemia AML 47 related hematological toxicity 47 inhibitor RG# 47 locoregional disease 47 serum concentrations 47 severe exacerbations 47 nadolol 47 mso font pitch 47 achieved sustained virological 47 % CI #.#-#.# [007] 47 Matt Guidera Buell 47 IFN α 47 urate lowering therapy 47 mCi m 2 47 desvenlafaxine succinate 47 HBV DNA 47 mg m 47 segment binary restenosis 47 Unified Parkinson Disease 47 baseline Hb 47 pituitary adenomas 47 Kaplan Meier estimate 47 tolerated dose MTD 47 HBV infections 47 Lubiprostone 47 definite stent thrombosis 47 nucleoside analog 47 tipranavir ritonavir 47 virologic suppression 47 peginterferon alpha 2a 47 invasive ductal breast cancer 47 clodronate 47 Peginterferon 47 ZOMIG Nasal Spray 47 beclomethasone dipropionate 47 Stomatitis 47 tenofovir emtricitabine 47 #.#mg/dL 47 - -Books Market Segmentation 47 RECIST 47 atheroma volume 47 unresectable tumors 47 investigational oral inhibitor 47 XIENCE V PROMUS Stent 47 stomatitis pharyngitis 47 salmeterol fluticasone 47 detemir 47 Postoperative complications 47 serum testosterone 47 μg l 47 recurrent VTE 47 BENICAR HCT 47 Severity MSCS score 47 pharmacokinetic equivalence 47 systolic dysfunction 47 baseline PASI 47 CYT# QbG# 47 seropositive 47 HbA1C 47 heavily pretreated 47 progressive neurodegenerative disorder 47 erythrocyte sedimentation rate 47 ABC/3TC 47 CIN2 + 47 ACR Pedi 47 maximal treadmill 47 TNF receptor 47 hematological parameters 47 LPV r 47 lispro 47 amprenavir 47 Symptom onset 47 beta 1a 47 anemia hemoglobin 47 death reinfarction 47 #R #R #R [002] 47 FTC TDF 47 chlorambucil 47 REVIVE Diabetes 47 repeat paracentesis 47 #mg/dL [002] 47 achieving PASI 47 androgen ablation therapy 47 p#HER# positive 47 plasma uric acid 47 HBeAg negative patients 47 CsA 47 tsp vanilla extract 47 plus COPEGUS 47 Ocrelizumab 47 ≥ 47 CMV disease 47 Natalizumab 47 6MW distance 47 specific antigen PSA 47 peginterferon alfa 47 versus +9 47 μg ml 47 Uncontrolled hypertension 47 receiving antiretroviral therapy 47 ® lenalidomide 47 SUVmax 47 glycosylated hemoglobin levels 47 cells μL 47 CSDs Dr Pepper 47 mL min 47 Meets Primary Endpoint 47 ng dl 47 ispinesib administered 47 nicardipine 47 binary restenosis 47 TOTAL REV 47 jason.hovet @ thomsonreuters.com 47 mEq 47 gastrointestinal stromal tumors 47 deferred drydocking charges 47 pain palliation 47 virologic responses 47 CSBMs 47 symptomatic pulmonary embolism 47 Enq# Index 47 Contrave# 47 Montgomery Asberg Depression 47 Dose escalation 47 UPDRS scores 47 adalimumab Humira 47 μmol l 47 NATRECOR ® 47 Back Guar 47 Eur Respir J 46 adriamycin 46 baseline FEV 46 Remission Maintenance 46 Nephrol 46 incidence ≥ 46 viral load 46 PREZISTA ritonavir 46 Teriflunomide 46 to#.# [003] 46 OS = ISD/#/#/# 46 left ventricular diastolic 46 Relapsed Refractory 46 AVODART 46 creatinine clearance CrCl 46 estramustine 46 recurrent metastatic 46 coinfected patients 46 Brief Psychiatric 46 migalastat HCl 46 #mg/dL [001] 46 BRIM2 46 n Cooling Degree 46 leukocyte count 46 recurrent NSCLC 46 spirometric 46 IQR 46 viremia 46 amoxicillin clavulanate 46 nausea somnolence 46 Scale EDSS 46 HBeAg 46 vincristine doxorubicin 46 μg liter 46 prospectively stratified 46 CC genotype 46 hormone receptor negative 46 FROVA 46 IELT 46 graft dysfunction 46 low dose Iluvien 46 nucleoside naive patients 46 WOMAC TM 46 vidofludimus 46 HOMA IR 46 T#I [002] 46 Active Trader DARTs 46 % CI #.#-#.# [001] 46 #μg [002] 46 FDG PET imaging 46 Treatment Naive Patients 46 activated partial thromboplastin 46 icatibant 46 bleeding pallor 46 pegaptanib 46 confidence interval #.#-#.# 46 ìg 46 dalteparin 46 ALT elevations 46 Vested Partnership 46 Gentle Path compound 46 lumiliximab 46 virologic breakthrough 46 symptom onset 46 glycosylated hemoglobin 46 Homes Sold tbr 46 CK MB 46 poor metabolizers 46 microg 46 LTIFR 46 DJI #.# 46 receiving Vectibix monotherapy 46 HBeAg positive patients 46 MVax 46 metastatic carcinoid tumors 46 #.#mmol l [002] 46 receiving golimumab 46 DLQI 46 glycated hemoglobin 46 ascending doses 46 elevated LDH 46 NIHSS 46 ALVESCO 46 RLAI 46 SITC code 46 thyroglobulin 46 QD dosing 46 ibandronate 46 biochemical recurrence 46 Retreatment 46 ® fluocinonide Cream 46 ADDITIONAL PAID IN 46 febrile neutropenia